← RIGEL PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $20.4m |
$4.5m
-78.00%
|
$44.5m
+892.62%
|
$59.3m
+33.20%
|
$108.6m
+83.21%
|
$149.2m
+37.39%
|
$120.2m
-19.43%
|
$116.9m
-2.79%
|
$179.3m
+53.38%
|
$294.3m
+64.15%
|
$276.8m
-5.95%
|
|
| Cost of Revenue | $69.2m |
$46.3m
-33.15%
|
$287k
-99.38%
|
$906k
+215.68%
|
$895k
-1.21%
|
$1.1m
+21.01%
|
$1.7m
+61.50%
|
$7.1m
+306.52%
|
$18.6m
+162.26%
|
$19.6m
+5.22%
|
$23.8m
+21.50%
|
|
| Gross Profit (Calculated) (derived) | ($48.8m) |
($41.8m)
+14.43%
|
$44.2m
+205.83%
|
$58.4m
+32.02%
|
$107.7m
+84.52%
|
$148.2m
+37.53%
|
$118.5m
-20.02%
|
$109.8m
-7.36%
|
$160.6m
+46.33%
|
$274.7m
+70.99%
|
— | |
| Research and Development Expense | — | — | — | — | — | — | — | — | — | $33.3m | $43.7m | |
| General and Administrative Expense | $20.9m | $37.8m | $70.0m | $74.6m | $76.6m | $91.9m | $112.5m | $105.7m | $113.1m | $115.9m | — | |
| Amortization of Intangible Assets | — | — | — | — | — | — | $100k | $1.1m | $2.1m | $2.4m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | ($69.7m) |
($79.6m)
-14.16%
|
($72.7m)
+8.71%
|
($69.1m)
+4.94%
|
($29.0m)
+58.07%
|
($12.5m)
+56.87%
|
($55.5m)
-344.54%
|
($20.5m)
+63.11%
|
$24.2m
+218.06%
|
$125.5m
+418.63%
|
$87.0m
-30.62%
|
|
| Interest Expense (non-operating) | — | — | — | $335k | $1.4m | $4.9m | $3.7m | $6.9m | $7.9m | $7.3m | $5.8m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $69.7m | $79.6m | $72.7m | $69.1m | $29.0m | ($17.3m) | ($58.6m) | ($25.1m) | $18.4m | $121.8m | $85.6m | |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | — | — | — | — | $655k | ($236.3m) | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | — | — | $605k | — | — | $881k | ($245.2m) | ($236.3m) | |
| Net Income (Loss) Attributable to Parent | ($69.2m) |
($78.0m)
-12.68%
|
($70.5m)
+9.63%
|
($66.9m)
+5.09%
|
($29.7m)
+55.54%
|
($17.9m)
+39.77%
|
($58.6m)
-226.97%
|
($25.1m)
+57.16%
|
$17.5m
+169.69%
|
$367.0m
+1999.08%
|
$321.9m
-12.29%
|
|
| Earnings Per Share, Basic | — | — | — | ($0.40) | ($0.18) | ($0.11) | ($0.34) | ($0.14) | $0.99 | $20.40 | $17.82 | |
| Earnings Per Share, Diluted | — | — | — | — | — | ($0.11) | ($0.34) | ($0.14) | $0.99 | $19.48 | $16.89 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | 170.5m | 172.4m | 174.0m | 17.6m | 18.0m | 18.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 170.5m | 172.4m | 174.0m | 17.7m | 18.8m | 19.6m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $90.1m | $84.1m | $117.2m | $128.4m | $137.6m | $161.7m | $175.8m | $137.4m | $155.1m | $168.8m | — |